NEW
YORK, March 20, 2025 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders
of Geron Corporation (NASDAQ: GERN).
Shareholders who purchased shares of GERN during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/geron-corporation-loss-submission-form/?id=137097&from=4
CLASS PERIOD: June 7, 2024
to February 25, 2025
ALLEGATIONS: According to the complaint, defendants
provided investors with material information concerning defendants'
expectations for the launch and growth potential of Rytelo
(imetelstat). Defendants' statements included, among other things,
confidence in Geron's ability to capitalize on the purportedly
significant unmet need for the drug and to execute on its
commercial plan to target first-line ESA ineligible patients, while
continually minimizing the risks associated with the burden of the
weekly monitoring requirement for Rytelo and the impacts of
seasonality and existing competition on the drug's sales. On
February 26, 2025, Geron announced
its financial results for the fourth quarter of fiscal 2024,
disclosing that Rytelo's growth had flattened over the preceding
months. The Company attributed the diminished growth on
seasonality, competition, lack of awareness for Rytelo, and the
burden of the monitoring requirement necessary for the drug
treatment. Following this news, the price of Geron's
common stock declined dramatically. From a closing market price of
$2.37 per share on February 25, 2025, Geron's stock price fell to
$1.61 per share on February 26, 2025, a decline of about 32.07% in
the span of just a single day.
DEADLINE: May 12, 2025
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/geron-corporation-loss-submission-form/?id=137097&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of GERN during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is May 12, 2025. There is no cost or
obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/class-action-filed-against-geron-corporation-gern-seeking-recovery-for-investors--contact-the-gross-law-firm-302406353.html
SOURCE The Gross Law Firm
